Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD
Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Dec 5, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how probiotics, which are beneficial bacteria, combined with special nutrition given through a feeding tube (called enteral nutrition), can help reduce infections after a specific type of surgery known as pancreaticoduodenal surgery. The goal is to see if this combination can help patients recover more smoothly and avoid complications related to infections after their surgery.
To participate in this trial, you need to be an adult over 18 years old and scheduled for elective pancreaticoduodenal surgery, meaning it's planned in advance rather than done in an emergency. It's important that you understand the study and can give your consent to take part. However, if you have recently used probiotic products or antibiotics, or if you have certain health conditions that make the surgery high-risk, you won't be eligible. If you decide to join, you can expect to receive either the probiotics and enteral nutrition or standard care, and your recovery will be closely monitored to see how well you do after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients greater than 18 years of age;
- • Indication for elective pancreaticoduodenal surgery;
- • Patients who understand the nature of the trial and are willing and able to provide written consent
- Exclusion Criteria:
- • . Current or recent (within the previous 1 month) use of probiotic-based products or antibiotic therapy medications.
- • Inability to tolerate PD due to cardiopulmonary function and other parameters
- • Received radiotherapy before surgery
- • Emergency PD surgery
- • Pregnant and breastfeeding women
About The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is a leading academic medical institution in China, renowned for its commitment to advanced healthcare, research, and medical education. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative medical research aimed at improving patient outcomes. With a focus on translational medicine, the institution fosters collaborations between clinicians and researchers to accelerate the development of novel therapies and enhance the understanding of complex diseases. Through its rigorous adherence to ethical standards and regulatory compliance, the hospital is dedicated to advancing medical knowledge and contributing to the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported